Phase II Study of Imatinib Mesylate Plus Hydroxyurea in Adults With Recurrent Glioblastoma Multiforme

2005331 citationsJournal Articlebronze Open Access

Authors

Imatinib mesylate plus hydroxyurea is well tolerated and associated with durable antitumor activity in some patients with recurrent GBM.

Published in: Journal of Clinical Oncology

Volume 23, Issue 36, pp. 9359-9368

Field-Weighted Citation Impact: 16.68